20 Participants Needed

Xenon Inhalation Therapy for Depression

SA
AN
Overseen ByAndrew Nierenberg, MD
Age: 18+
Sex: Any
Trial Phase: Phase < 1
Sponsor: Massachusetts General Hospital
Must be taking: Antidepressants, Mood stabilizers

Trial Summary

What is the purpose of this trial?

The investigators will test the hypothesis that inhaled xenon will produce a rapid improvement in depressive symptoms in patients suffering from treatment-resistant depression. Specifically, the investigators will conduct a parallel randomized, double-blind crossover study that will compare the effects of xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group) to the effects of nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group). A total of 20 severely depressed patients, 10 with major depressive disorder (MDD) and 10 with Bipolar Depression (BP), will be exposed in random order to N-TAU and X-TAU in a double-blind protocol.

Research Team

AN

Andrew Nierenberg, MD

Principal Investigator

Massachussetts General Hospital

Eligibility Criteria

Adults aged 18-65 with severe depression or bipolar disorder, who haven't responded to standard treatments, can join. They must understand the trial and consent, have stable medication for four weeks, reliable transport, and a psychiatrist's approval. Pregnant women, active substance abusers, smokers, those with certain medical conditions or taking benzodiazepines are excluded.

Inclusion Criteria

Has a treating psychiatrist who is in agreement with the patient's participation in the study, and aware of the safety plan in the protocol.
I do not have any serious lung conditions.
I have been on a stable antidepressant or mood stabilizer for over 4 weeks.
See 5 more

Exclusion Criteria

I am currently taking a benzodiazepine medication.
Unwilling or unable to comply with study procedures.
I do not have any uncontrolled serious health conditions.
See 8 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive one session of xenon inhalation and one session of nitrogen-oxygen inhalation in a randomized, double-blind crossover design

1 day
2 sessions (in-person)

Follow-up

Participants are monitored for changes in depressive symptoms using HDRS and QIDS-C at predefined intervals

1 week
Assessments at 40, 80, 110, and 230 minutes post-administration and 1, 3, and 7 days post-administration

Treatment Details

Interventions

  • Nitrogen gas Inhalation Therapy
  • Xenon Inhalation Therapy
Trial Overview The study is testing if inhaling xenon gas helps improve symptoms of depression faster than nitrogen gas when added to usual treatment. It's a double-blind crossover trial where patients try both options randomly without knowing which one they're getting.
Participant Groups
2Treatment groups
Active Control
Placebo Group
Group I: X-TAU (xenon)Active Control1 Intervention
Xenon is a potent antiglutaminergic agent that has been used as an anesthetic with minimal side effects, has neuroprotective effects consistent with antidepressants and has the potential to be a novel antidepressant drug. - xenon-oxygen (35:65 ratio by volume) added to treatment as usual (X-TAU group)
Group II: N-TAU (nitrogen-placebo)Placebo Group1 Intervention
Nitrogen-oxygen (35:65 ratio by volume) added to treatment as usual (N-TAU group)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Massachusetts General Hospital

Lead Sponsor

Trials
3,066
Recruited
13,430,000+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security